Genomic landscape for tumours: Is there any evidence?

There are numerous studies and I have highlighted the most pertinent aspects of the molecular landscape to bring you to speed. In one word-potential. Molecular amalgamation of the studies in clinic is time consuming, expensive and not standardised. Most important aspect of this paper? 10 gene signature which predicts radiosenstivity. Although, this has been picked […]

Is physician-reported data better than patient-reported outcomes? (Example of prostate cancer)

Reason for inclusion: An accurate assessment of treatment-related complications is missing in follow-ups. Practise changing statement: Physician assessment+ Patient report outcomes on a continuous basis will help more to define the extent of problems. We also need more quantitative measures. Page 1 specific information before the design of any particular research study. Patient-specific information may […]